Hair Loss
Conditions
Interventions
Group 1:Use LT010 paint-? as required by the protocol
Group 2:Use LT010 Paint-? for 3 consecutive days in the first week and once a week thereafter
Group 3:Use LT010 Paint-? for 3 consecutive days in the first week and once a week thereafter
Group 4:Use LT010 Paint-?, apply continuously three times in the first week of every four weeks, and once a week thereafter, all continuously for 52 weeks
Group 5:Use LT010 Paint-?, apply continuously three times in the first week of every four weeks, and once a week thereafter, all continuously for 52 weeks
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Healthy males aged 18 to 60 years; 2. Clinically diagnosed with androgenetic alopecia, classified as Hamilton-Norwood stages III, IV, or V; 3. No special hairdressing procedures (e.g., dyeing, perming, styling) within the past month; 4. Willingness to maintain consistent hairstyle, colour, and length throughout the study period, refraining from specialised hair care products or treatments; 5. Agreement to adhere to the trial treatment regimen and follow-up schedule, voluntary enrolment, and written informed consent.
Exclusion criteria
Exclusion criteria: 1. Individuals suffering from other types of hair loss conditions, such as alopecia areata or diffuse alopecia, syphilitic alopecia, scarring alopecia, malnutrition, or hair loss resulting from chemotherapy/radiotherapy; 2. Individuals with scalp dermatoses affecting treatment efficacy assessment, scalp trauma, or other scalp conditions requiring topical medication, such as fungal or bacterial infections, severe seborrhoeic dermatitis, scalp psoriasis, contact dermatitis, severe folliculitis, or scalp atrophy; 3. Individuals who have previously undergone hair transplantation; 4. Individuals who have used cosmetics, health supplements, or other products claiming hair loss prevention or hair growth benefits within the past six months; 5. Patients with systemic diseases affecting the cardiovascular, endocrine, or metabolic systems, or those with immunodeficiency or autoimmune disorders; 6. Patients currently undergoing treatment for asthma or other chronic respiratory diseases, or those with infectious diseases; 7. Individuals with psychiatric or psychological disorders; 8. Those with highly sensitive constitutions; 9. Participants who have taken part in prior studies or other clinical trials within the last six months; 10. Individuals who have undergone anticancer chemotherapy within the last six months; 11. Those deemed unsuitable for trial participation based on clinical assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall hair density;Local hair density; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Safety assessment;Satisfaction score; | — |
Countries
China
Contacts
Public ContactLi Li
West China Hospital, Sichuan University
Outcome results
None listed